Teva moexipril decision
Executive Summary
Teva plans to continue distribution of the antihypertensive agent moexipril following decision by a federal court of appeals to overturn a March 2003 New Jersey district court's summary judgement, which found that Teva did not infringe Schwarz' moexipril patent (no. 4,742,450). Teva began selling moexipril in May 2003, immediately following its May 8 approval. Schwarz licensed rights to Univasc (moexipril) from Warner-Lambert (now Pfizer)...
Teva plans to continue distribution of the antihypertensive agent moexipril following decision by a federal court of appeals to overturn a March 2003 New Jersey district court's summary judgement, which found that Teva did not infringe Schwarz' moexipril patent (no. 4,742,450). Teva began selling moexipril in May 2003, immediately following its May 8 approval. Schwarz licensed rights to Univasc (moexipril) from Warner-Lambert (now Pfizer).... |